• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Scott Olsen to lead federal advocacy at PhRMA

Scott Olsen to lead federal advocacy at PhRMA

September 14, 2016
CenterWatch Staff

The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced Scott Olsen will join the association as senior vice president for federal advocacy. A seasoned Democratic strategist, Olsen returns to PhRMA on October 3, 2016, to lead PhRMA’s federal government relations team.

Olsen is a recognized leader in federal government relations with over 20 years of experience working with Democrats and Republicans on Medicare and Medicaid policy. He began his career working in the office of then-Senator Max Baucus (D-MT). As the Senator’s top health policy aide, he supported the Senator’s healthcare work on the Senate Finance Committee. He previously spent several years at PhRMA as both the lead Democratic lobbyist and Senate team leader. During that time he worked closely on the passage of the Medicare Modernization Act in 2003.

“As PhRMA continues to tell the story of the life-changing work of America’s biopharmaceutical companies while advocating for patient access to new treatments, Scott’s experience finding common ground with Democrats and Republicans is a vital addition to the association,” said Stephen J. Ubl, president and CEO of PhRMA.

Olsen most recently spent nearly a decade with Amgen including as executive director of federal government affairs in Washington, D.C. Fluent in Japanese, Olsen was subsequently promoted to manage Amgen’s investment opportunities in Japan, China, Russia and the European Union.

“This is an exciting time in America’s biopharmaceutical industry as companies continue the tireless work of researching and developing new treatments and cures for patients,” Olsen said. “I am especially looking forward to helping PhRMA advance bipartisan solutions to our nation’s health care challenges.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing